


# CHAPTER 7



## REFERENCE

- Ali, S.L., 1989. Nifedipine. In: Florey, K. (Ed.), *Analytical profiles of drug substances*, vol. 18. Academic Press, New York, pp. 221–288.
- Appel, L.E., Zentner, G.M., 1991. Use of modified ethyl cellulose lattices for microporous coating of osmotic tablets. *Pharm.Res.* 8, 600–604.
- Ayer, A., Theeuwes, F., Wong, P.S.L., 1988. Process for increasing solubility of drug. US Patent No. 4,732,915.
- Ayer, A.D., Theeuwes, F., 1980. Osmotic system with distribution zone for dispensing beneficial agent. US Patent No. 4,200,098.
- Ayer, A.D., Wong, P.S.L., 1988. Dosage form comprising solubility regulating member, US Patent No. 4,755,180.
- Banker, G.S., Anderson, N.R., 1987. Tablets. In: Lachman, L., Liberman, H.A., Kanig, J.L. (Eds.), *The Theory and Practice of Industrial Pharmacy*, third edition, Verghese Publishing House, Mumbai, pp 293–345.
- Bettini, R., Catellani, P.L., Santi, P., Massimo, G., Peppas, N.A., Colombo, P., 2001. Translocation of drug particles in HPMC matrix gel layer: effect of drug solubility and influence on release rate. *J. Control. Release* 70, 383–391.
- Burger, A., Koller, K.T., 1996. Polymorphism and pseudopolymorphism on nifedipine. *Sci. Pharm.* 64, 293–301.
- Chen, C.M., Chou, J.C.H., 1998. Once daily pharmaceutical tablet having a unitary core. US Patent No. 5,837,379.
- Chen, C.M., Lee, D.Y., Xie, J., 1998. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ. US Patent No. 5,736,159.
- Chiou, W.L., Riegelman, S., 1970. Oral absorption of griseofulvin in dogs: increased absorption via solid dispersion in polyethylene glycol 6000. *J. Pharm. Sci.* 59, 937–942.
- Chutimaworapan, S., Ritthidej, G.C., Yonemochi, E., Oguchi, T., Yamamoto, K., 2000. Effect of water-soluble carriers on dissolution characterization of nifedipine solid dispersions, *Drug Dev. Ind. Pharm.* 26, 1141–1150.
- Colombo, P., Bettini, R., Peppas, N.A., 1999. Observation of swelling process and diffusion front position during swelling in hydroxypropyl methylcellulose (HPMC) matrices containing a soluble drug. *J. Control. Release* 61, 83–91.
- Costa, P., Lobo, J.M.S., 2001. Modeling and comparison of dissolution profiles. *Eur. J. Pharm. Sci.* 13, 123–133.
- Curatolo, W.J., 1989. Dispensing devices powered by lyotropic liquid crystals, US patent 5,030,452.

Curatolo, W.J., 1992. Dispensing devices powered by lyotropic liquid crystals. US Patent 5,108,756.

Defang, O., Shufang, N., Wei, L., Hong, G., Hui, Liu., Weisan, P., 2005. In vitro and In vivo evaluation of two extended release preparations of combination metformin and glipizide. *Drug Dev. Ind. Pharm.* 31, 677-685.

DeVane, C.L., 1998. Differential pharmacology of newer antidepressants. *J. Clin. Psychiatry*. 59 Suppl 20, 85 - 93.

Dong, L., Shafi, K., Wan, J., Wong, P., 2000. A novel osmotic delivery system: L-OROS Softcap, in: *Proceedings of the International Symposium on Controlled Release of Bioactive Materials*, Paris. CD-ROM.

Dong, L., Wong, P., Espinal, S., 2001. L-OROS HARDCAP: A new osmotic delivery system for controlled release of liquid formulation, in: *Proceedings of the International Symposium on Controlled Release of Bioactive Materials*, San Diego, CD-ROM.

Durig, T., Fassihi, R., 2002. Guar-based monolithic matrix systems: Effect of ionizable and non-ionizable substances and excipients on gel dynamics and release kinetics. *J. Control. Release* 80, 45-56.

Eckert, T., Muller, J., 1977. On polymorphic forms of nifedipine from supercooled melts. *Arch. Pharm.* 310, 116-118.

Ficarra, R., Ficarra, P., Di Bella, M.R., Raneri, D., Tommasini, S., Calabro, M.L., Villari, A., Coppolino, S., 2000. Study of the inclusion complex of atenolol with cyclodextrins. *J. Pharm. Biomed. Anal.* 23, 231-236.

Garg, A., Gupta, M., Bhargava, H.N., 2007. Effect of formulation parameters on the release characteristics of propranolol from asymmetric membrane coated tablets. *Eur. J. Pharm. Bio.* 67, 725-731.

Geerke, J.H., 1997. Method and apparatus for forming dispenser delivery ports. US Patent No. 5,658,474.

Gondaliya, D., Pundarikakshudu, K., 2003. The fabrication and evaluation of the formulation variables of controlled porosity osmotic drug delivery system with diltiazem hydrochloride. *Pharm. Tech.* 58-68.

Grundy, J.S., Foster, R.T., 1996. The nifedipine gastrointestinal therapeutic system (GITS): evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. *Clin. Pharmacokinet.* 30, 28-51.

Gutierrez, M.A., Stimmel, G.L., Aiso, J.Y., 2003. Venlafaxine: A 2003 update. *Clin. Ther.* 25, 2138 - 2154.

Herbig, S.M., Cardinal, J.R., Korsmeyer, R.W., Smith, K.L., 1995. Asymmetric-membrane tablet coatings for osmotic drug delivery. *J. Control. Release* 35, 127-136.

Hoffman, B.B., 2001. Catecholamines, sympathomimetics drugs and adrenergic receptor antagonists. In: Hardman, J.G., Limbird, L.E., (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, tenth edition. McGraw-Hill, New York, pp 255-257.

Hogan, J.E., 1989. Hydroxypropyl methylcellulose sustained release technology. *Drug Dev. Ind. Pharm.* 15, 975-999.

Jensen, J.L., Appel, L.E., Clair, J.H., Zentner, G.M., 1995. Variables that affect the mechanism of drug release from osmotic pumps coated with acrylate / methacrylate copolymer latexes. *J. Pharm. Sci.* 84, 530-533.

Kamba, M., Seta, Y., Kusai, A., Ikeda, M., Nishimura, K., 2000. A unique dosage form to evaluate the mechanical destructive forces in the gastrointestinal tract. *Int. J. Pharm.* 208, 61-70.

Kamp, O., Sieswerda, G.T., Visser, C.A., 2003. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. *Am. J. Cardiol.* 92, 344-348.

Kendall, M.J., Maxwell, S.R., Sandberg, A., Westergren, G., 1991. Controlled release metoprolol. Clinical pharmacokinetic and therapeutic implications. *Clin. Pharmacokinet.* 21, 319-325.

Khanna, S.C., 1991. Therapeutic system for sparingly soluble active ingredients. US Patent 4,992,278.

Khurahashi, H., Kami, H., Sunada, H., 1996. Influence of physicochemical properties on drug release rate from Hydroxypropyl methylcellulose matrices. *Chem. Pharm. Bull.* 44, 829-832.

Koparkar, A.D., Shah, S.B., 1994. Oral osmotic system for slightly soluble active agents. US Patent 5,284,662.

Korsmeyer, R.W., Gurny, R., Doelker, E., Buri, P., Peppas, N.A., 1983. Mechanisms of solute release from porous hydrophilic polymers. *Int. J. Pharm.* 15, 25-35.

Kuchiki, A., Nakagawa, H., Tohgo, K., Konda, S., Iwane, I., Takahashi, K., 1980. Dissolution and absorption of nifedipine from nifedipine-polypyrrolidone coprecipitation. *Drug Dev. Ind. Pharm.* 6, 137-190.

Law, S.L., Lo, W.Y., Lin, F.M., Chaing, C.H., 1992. Dissolution and absorption of nifedipine in polyethylene glycol solid dispersion containing phosphatidylcholine. *Int. J. Pharm.* 84, 161-166.

Lin, C.W., Cham, T.M., 1996. Effect of particle size on the available surface area of nifedipine from nifedipine polyethylene glycol 6000 solid dispersions. *Int. J. Pharm.* 127, 261-272.

Lin, Y., Ho, H., 2003. Investigations on the drug releasing mechanism from an asymmetric membrane coated capsule with an in situ formed delivery orifice. *J. Control. Release* 89, 57–69.

Liu, H., Yang, X.G., Nie, S.F., Wei, L.L., Zhou, L.L., Liu, H., Tang, R., Pan, W.S., 2007. Chitosan-based controlled porosity osmotic pump for colon-specific delivery system: Screening of formulation variables and in vitro investigation. *Int. J. Pharm.* 332, 115–124.

Liu, L., Khang, G., Rhee, J.M., Lee, H.B., 2000b. Monolithic osmotic tablet system for nifedipine delivery. *J. Control. Release* 67, 309–322.

Liu, L., Ku, J., Khang, G., Lee, B., Rhee, J.M., Lee, H.B., 2000a. Nifedipine controlled delivery by sandwich osmotic tablet system. *J. Control. Release* 68, 145–156.

Liu, L., Wang, X., 2007. Solubility-modulated monolithic osmotic pump tablet for atenolol delivery. *Eur. J. Pharm. Bio. In Press*, Corrected Proof.

Magruder, P.R., Barclay, B., Wong, P.S.L., Theeuwes, F., 1988a. Composition comprising salbutamol, US Patent No. 4,751,071.

Magruder, P.R., Barclay, B., Wong, P.S.L., Theeuwes, F., 1988b. Constant release system with pulsed release, US Patent 4,777,049.

Makhija, S.N., Vavia, P.R., 2003. Controlled porosity osmotic pump-based controlled release systems of pseudoephedrine I cellulose acetate as a semipermeable membrane. *J. Control. Release* 89, 5–18.

Mathews, B.R., 1999. Regulatory aspects of stability testing in Europe. *Drug Dev. Ind. Pharm.* 25, 831–856.

McClelland, G.A., Sutton, S.C., Engle, K., Zentner, G.M., 1991. The solubility-modulated osmotic pump: In vitro / in vivo release of diltiazem hydrochloride. *Pharm. Res.* 8, 88–92.

McClelland, G.A., Sutton, S.C., Engle, K., Zentner, G.M., 1991. The solubility-modulated osmotic pump: In vitro / in vivo release of diltiazem hydrochloride, *Pharm. Res.* 8 (1991) 88–92.

McClelland, G.A., Zentner, G.M., 1990. Solubility modulated drug delivery system. US Patent 4,946,686.

Mehta, K.A., Serpil Kislalioglu, M., Phuapradit, W., Waseem Malick, A., Ke, K., Shah, N.H. In vivo release performance of nifedipine in dogs from a novel Eudragit-based multi-unit erosion matrix. *Drug Del. Tech.* (available online).

Moneghini, M., Carcano, A., Zingone, G., Perissutti, B., 1998. Studies in dissolution enhancement of atenolol. *Int. J. Pharm.* 175, 177–183.

- Moore, J.W., Flanner, H.H., 1996. Mathematical comparison of dissolution profiles. *Pharm. Technol.* 20, 64 – 74.
- Narasimhan, B., 2001. Mathematical models describing polymer dissolution: consequences for drug delivery. *Adv. Drug Deliv. Rev.* 48, 195–210.
- Nemeroffa, C.B., Thaseb, M.E., On behalf of the EPIC 014 Study Group, 2007. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. *J. Psychiatric Research.* 41, 351 – 359.
- Okimoto, K., Miyake, M., Ohnishi, N., Rajewski, R.A., Stella, V.J., Irie, T., Uekama, K., 1998. Design and evaluation of an osmotic pump tablet (OPT) for prednisolone, a poorly water soluble drug, using (SBE)-b-7m-CD. *Pharm. Res.* 15, 1562–1568.
- Okimoto, K., Ohike, A., Ibuki, R., Aoki, O., Ohnishi, N., Irie, T., Uekama, K., Rajewski, R.A., Stella, V.J., 1999b. Design and evaluation of an osmotic pump tablet (OPT) for chlorpromazine using (SBE)-b-7m-CD. *Pharm. Res.* 16, 549–554.
- Okimoto, K., Ohike, A., Ibuki, R., Aoki, O., Ohnishi, N., Rajewski, R.A., Stella, V.J., Irie, T., Uekama, K., 1999c. Factors affecting membrane-controlled drug release for an osmotic pump tablet (OPT) utilizing (SBE)-b-7m-CD as both a solubilizer and osmotic agent. *J. Control. Release* 60, 311–319.
- Okimoto, K., Rajewski, R.A., Stella, V.J., 1999a. Release of testosterone from an osmotic pump tablet utilizing (SBE)-b-7m-CD as both a solubilizing and an osmotic pump agent. *J. Control. Release* 58, 29–38.
- Prabakaran, D., Singh, P., Kanaujia, P., Vyas, S.P., 2003. Effect of hydrophilic polymers on the release of diltiazem hydrochloride from elementary osmotic pumps. *Int. J. Pharm.* 259, 173–179.
- Rani, M., Surana, R., Sankar, C., Mishra, B., 2003. Development and biopharmaceutical valuation of osmotic pump tablets for controlled delivery of diclofenac sodium. *Acta. Pharm.* 53, 263-273.
- Robinson, J.R., 1987. Basics of controlled drug delivery. In : Robinson, J.R., Lee, V.H. (Eds.), *Controlled drug delivery*, second edition, Marcel Dekker Inc., New York, pp. 4-40.
- Rudnic, E.M., Burnside, B.A., Flanner, H.H., Wassink, S.E., Couch, R.A., Pinkett, J.E., 2000. Osmotic drug delivery system, US Patent 6,110,498.
- Sako, K., Sawada, T., Nakashima, H., Yokohama, S., Sonobe, T., 2002. Influence of water soluble fillers in hydroxypropyl methylcellulose matrices on in vitro and in vivo drug release. *J. Control. Release* 81, 165–172.
- Santus, G., Baker, W.R., 1995. Osmotic drug delivery: a review of patent literature. *J. Control. Release* 35, 1–21.

- Sastry, S.V., Khan, M.A., 1998. Aqueous based polymeric dispersion: Plackett–Burman design for screening of formulation variables of Atenolol Gastrointestinal Therapeutic System. *Pharm. Acta Helv.* 73,105–112.
- Sastry, S.V., Reddy, I.K., Khan, M.A., 1997. Atenolol gastrointestinal therapeutic system: optimization of formulation variables using response surface methodology. *J. Control. Release* 45, 121–130.
- Sastry, S.V., Reddy, I.K., Khan, M.A., 1997. Atenolol gastrointestinal therapeutic system: optimization of formulation variables using response surface methodology. *J. Control. Release* 45, 121–130.
- Schmid, E.F., Smith, D.A., 2005. Keynote review: Is declining innovation in the pharmaceutical industry a myth? *Drug Discovery Today* 10, 1031–1039.
- Serajuddin, A.T.M., 1999. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems and recent breakthroughs. *J. Pharm. Sci.* 88, 1058–1066.
- Shokri, J., Ahmadi, P., Rashidi, P., Shahsavari, M., Rajabi-Siahboomi, A., Nokhodchi, A., 2007. Swellable elementary osmotic pump (SEOP): An effective device for delivery of poorly water-soluble drugs. *Eur. J. Pharm. Bio. In Press*, Corrected Proof.
- Speers, M., Bonnano, C., 1999. Economic aspects of controlled drug delivery. In: Mathiowitz, E., (Eds.), *Encyclopedia of Controlled Drug Delivery*. Wiley, New York, pp. 341–347.
- Stephens, S.I., Wong, P.S.L., 1989. Dosage form with improved delivery capability. U.S. Patent No. 4,863,456.
- Stupak, E.I., Bates, T.R., 1972. Enhanced absorption and dissolution of reserpine from reserpine-polyvinylpyrrolidone coprecipitates. *J. Pharm. Sci.* 61, 400–404.
- Sugimoto, I., Kuchiki, A., Nakagawa, H., Tohgo, K., Kondo, S., Iwane, I., Takahashi, K., 1980. Dissolution and absorption of nifedipine from nifedipine-polyvinylpyrrolidone coprecipitates. *Drug Dev. Ind. Pharm.* 6, 137–160.
- Sugimoto, M., Okagaki, T., Narisawa, S., Koida, Y., Nakajima, K., 1998. Improvement of dissolution characteristics and bioavailability of poorly water-soluble drugs by novel cogrinding method using water-soluble polymer. *Int. J. Pharm.* 160, 11–19.
- Sukuzi, H., Sunada, H., 1998. Influence of water-soluble polymers on the dissolution of nifedipine solid dispersions with combined carriers. *Chem. Pharm. Bulletin.* 46, 482–487.
- Swanson, D.R., Barclay, B.L., Wong, P.S.L., Theeuwes, F., 1987. Nifedipine gastrointestinal therapeutic system. *Am. J. Med.* 83, 3–9.
- Swanson, D., Edgren, D., 1982. Osmotic device that improves delivery properties of agent in situ. US Patent No. 4,326,525.

- Theeuwes, F., 1975. Elementary osmotic pump. *J. Pharm. Sci.* 64, 1987–1991.
- Theeuwes, F., 1977. Osmotic dispenser with gas generating means. US Patent 4,036,228.
- Theeuwes, F., 1984. Oral dosage form design: status and goals of oral osmotic systems technology, *Pharm. Int.* 5, 293–296.
- Theeuwes, F., Ayer, A.D., 1978. Osmotic devices having composite walls, US Patent No. 4,077,407.
- Theeuwes, F., Swanson, D., Wong P., Bonsen, P., Place, V., Heimlich, K., Kwan, K.C., 1983. Elementary osmotic pump for indomethacin. *J. Pharm. Sci.* 72, 253–258.
- Theeuwes, F., Swanson, D.R., Guittard, G., Ayer, A., Khanna, S., 1985. Osmotic delivery systems for the beta-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration. *Br. J. Clin. Pharmacol.* 19, 69S–76S.
- Thombre, A.G., 1997. Delivery device having encapsulated excipients. US Patent 5,697,922.
- Thombre, A.G., Appel, L.E., Chidlaw, M.B., Daugherty, P.D., Dumont, F., Evans, L.A.F., Sutton, S.C., 2004. Osmotic drug delivery using swellable-core technology. *J. Control. Release* 94, 75–89.
- Thombre, A.G., DeNoto, A.R., Gibbes, D.C., 1999. Delivery of glipizide from asymmetric membrane capsules using encapsulated excipients. *J. Control. Release* 60, 333–341.
- Turner, S., Federici, C., Hite, M., Fassihi, R., 2004. Formulation development and human in vitro-in vivo correlation for a novel, monolithic controlled release matrix system of high load and highly water-soluble drug niacin. *Drug Dev. Ind. Pharm.* 30, 797–807.
- Verma, R.K., Garg, S., 2004. Development and evaluation of osmotically controlled drug delivery system of glipizide. *Eur. J. Pharm. Sci.* 57, 513–525.
- Verma, R.K., Kaushal, A.M., Garg, S., 2003. Development and evaluation of extended release formulations of isosorbide mononitrate based on osmotic technology. *Int. J. Pharm.* 263, 9–24.
- Verma, R.K., Krishna, D. M., Garg, S., 2002. Formulation aspects in the development of osmotically controlled oral drug delivery systems. *J. Control. Release* 79, 7–27.
- Verma, R.K., Mishra, B., 1999. Studies on formulation and evaluation of oral osmotic pumps of nimesulide, *Pharmazie* 54, 74–75.
- Vippagunta, S.R., Maul, K.A., Tallavajhala, S., Grant, D.J.W., 2002. Solid-state characterization of nifedipine solid dispersions. *Int. J. Pharm.*, 236, 111–123.



Wong, P.S.L., Barclay, B.L., Deters, J.C., Theeuwes, F., 1986. Osmotic device for administering certain drugs. US Patent No. 4,765,989.

Zajc, N., Obreza, A., Bele, M., Srcic, S., 2005. Physical properties and dissolution behavior of nifedipine-mannitol solid dispersions prepared by hot melt method. *Int. J. Pharm.* 291, 51-58.

Zentner, G.M., McClelland, G.A., 1991. Solubility modulated drug delivery device, US Patent 4,994,273.

Zentner, G.M., McClelland, G.A., Sutton, S.C., 1991. Controlled porosity solubility and resin-modulated osmotic drug delivery systems for release of diltiazem hydrochloride. *J. Control. Release* 16, 237-244.

Zentner, G.M., Rork, G.S., Himmelstein, K.J., 1985a. The controlled porosity osmotic pump. *J. Control. Release* 1, 269-282.

Zentner, G.M., Rork, G.S., Himmelstein, K.J., 1985b. Osmotic flow through controlled porosity films: An approach to delivery of water soluble compounds. *J. Control. Release* 2, 217-229.